In intensive care medicine, various plasma proteins from Biotest are already in use today, for instance as volume and protein replacement in severe injuries and burns and also for the treatment of severe bacterial infections (e.g. sepsis).
Continuing this practice, Biotest is developing the IgM and IgA-enriched polyclonal antibody preparation trimodulin for the treatment of severe community acquired pneumonia.
Moreover, we work on innovations to improve products, for instance, to allow faster use of the blood clotting factor fibrinogen in life-threatening conditions.
